ArticleFrontiers in psychiatry2026
Altered gut microbiota and untargeted metabolomic features in patients with schizophrenia: a case-control study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mental disorders are among the leading causes of global disease burden, and their etiology spans genetic, environmental, and physiological factors. Emerging evidence suggests that the gut microbiota may contribute to the development of neuropsychiatric disorders through the microbiota-gut-brain axis. This study aimed to characterize differences in gut microbial composition and untargeted metabolomic profiles between patients with schizophrenia and healthy controls. Methods: Fecal samples were collected from 30 patients with schizophrenia and 30 healthy controls; 59 samples (30 patients and 29 controls) yielded qualified 16S rRNA gene sequencing data. Untargeted metabolomic profiling was performed by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Results: Compared with healthy controls, patients with schizophrenia showed reduced microbial richness and diversity together with marked separation in β-diversity. In an exploratory random forest ranking, Pseudocitrobacter, Hafnia-Obesumbacterium, and Escherichia-Shigella contributed most strongly to between-group discrimination. Escherichia-Shigella was significantly enriched in patients (median relative abundance 2.377% in group S vs. 0.119% in group H; q = 0.00031; Cliff's δ = 0.646), whereas Faecalibacterium (2.630% vs. 7.275%) and Agathobacter (0.903% vs. 2.874%) were more abundant in healthy controls. Untargeted metabolomics likewise revealed between-group differences that predominantly involved metabolites and pathways of amino acid and lipid metabolism. Conclusion: Patients with schizophrenia show alterations in gut microbial composition and untargeted metabolomic features, supporting an association between schizophrenia and microbiota-metabolite alterations. Future confirmation requires larger longitudinal cohorts and independent validation datasets. Owing to the small sample size, cross-sectional study design, and antipsychotic drug exposure, we could not disentangle disease-specific effects from medication-related effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.